Published on 3 Apr 2023 on Simply Wall St. via Yahoo Finance
Not Many Are Piling Into PhenomeX Inc. (NASDAQ:CELL) Just Yet
PhenomeX Inc.'s (NASDAQ:CELL) price-to-sales (or "P/S") ratio of 1.3x might make it look like a strong buy right now compared to the Life Sciences industry in the United States, where around half of the companies have P/S ratios above 4.4x and even P/S above 7x are quite common. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so limited.
Check out our latest analysis for PhenomeX
